scite.ai vs DrugCard

Scite helps research teams ask literature questions and get answers tied to full-text papers, not abstract snippets alone. Its Assistant searches across 280M+ full-text scholarly articles, and Smart Citations show whether later work supported, contradicted, or mentioned a finding.

General research chatbots guess when paywalls block the PDF. Scite licenses content from Wiley, SAGE, and 40+ other publishers, so it reads inside the paper and links each claim to a specific sentence you can verify in one click. That evidence-first design targets literature reviews where you need to know if a result still holds, not just that it exists.

Grad students run disputed-or-affirmed checks before citing a paper. R&D teams trace grants, clinical trials, and patents in one search. Pro users get API access, 2,500 MCP credits per month, and collections up to 10,000 papers. Scite also plugs into Claude, ChatGPT, and Zotero so answers show up inside existing workflows.

Teams use DrugCard to automate local and global medical literature screening without reading every journal cover to cover. The service monitors 2200+ local journals across 146+ countries, handles 100+ languages, and bundles modules like Simple Search, Regulatory Intelligence, an adverse event database, and eCTDlight. Marketing Authorization Holders, CROs, and PV freelancers are the audiences highlighted on the homepage.

Where generic literature databases stop at keyword alerts, DrugCard focuses on local-language journals and scanned print copies. The vendor claims proprietary OCR reaches up to 99% accuracy on average-quality scans and that customers see 50-70% time savings versus manual screening, with the homepage citing 60% savings and up to 3 minutes per article instead of 35.

Teams buy through demo requests rather than self-serve checkout. DrugCard also sells LQPPV, signal management, PSUR, ICSR, PSMF, and risk management services for orgs that want outsourced pharmacovigilance help alongside the software.